Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Kim, Han Joon ^a   Jeon, Beom S ^a   Lee, Won Y ^b   Lee, Myoung C ^c   Kim, Jae W ^d   Kim, Jong Min ^e   Ahn, Tae Beom ^f   Cho, Jinwhan ^b   Chung, Sun J ^c   Grieger, Frank ^g   Whitesides, John ^g   Boroojerdi, Babak ^g  

^a Seoul National University Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Dong A University   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Kyung Hee University Hospital   (South Korea)

^g UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ROPINIROLE; ROTIGOTINE; ANTIPARKINSON AGENT; INDOLE DERIVATIVE;

ADULT; AGED; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; ASTHENIA; BRADYKINESIA; DIZZINESS; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCLE RIGIDITY; OPEN STUDY; PARKINSON DISEASE; QUALITY OF LIFE; SOMNOLENCE; SOUTH KOREA; TREATMENT DURATION; TREMOR; XEROSTOMIA; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIPARKINSON AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 81155157964     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-100     Document Type: Article

References (21)

1. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonucelli U, Damier P, et al. Levodopa in the treatment of Parkinson's disease: Current controversies. Mov Disord 2004, 19:997-1005. 10.1002/mds.20243, 15372588.
2. Chase TN. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine. Neurology 1998, 50(Suppl5):S17-25.
3. Parkinson Study Group A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000, 23:34-44. Parkinson Study Group.
4. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484-1491. 10.1056/NEJM200005183422004, 10816186.
5. Parkinson Study Group Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial. Arch Neurol 2004, 61:1044-1053. Parkinson Study Group.
6. LeWitt PA, Lyons KE, Pahwa R, . on behalf of the SPSG Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007, 68:1262-1267. 10.1212/01.wnl.0000259516.61938.bb, 17438216, on behalf of the SPSG.
7. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6:513-520. 10.1016/S1474-4422(07)70108-4, 17509486.
8. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68:272-276. 10.1212/01.wnl.0000252355.79284.22, 17202432.
9. LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007, 30:256-265. 10.1097/wnf.0b013e318154c7c4, 17909303.
10. Lee JY, Lee EK, Park SS, Lim JY, Kim HJ, Kim JS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 2009, 24:1803-1810. 10.1002/mds.22678, 19562769.
11. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22:2398-2404. 10.1002/mds.21741, 17935234.
12. Trenkwalder C, Hoegl B, Kohnen R, et al. The Parkinson's disease sleep scale (PDSS) modified - preliminary results from a validation study. Mov Disord 2008, 23(Suppl1):S356.
13. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007, 22:1901-1911. 10.1002/mds.21596, 17674410.
14. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, . the RECOVER Study Group Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2010, the RECOVER Study Group.
15. Babic T, Boothmann B, Polivka J, Rektor I, Boroojerdi B, H J, et al. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin Neuropharmacol 2006, 29:238-242. 10.1097/01.WNF.0000228179.83335.65, 16855426.
16. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007, 64:676-682. 10.1001/archneur.64.5.676, 17502466.
17. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009, 24:1641-1649. 10.1002/mds.22643, 19514014.
18. Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY, et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 2009, 287:200-204. 10.1016/j.jns.2009.07.026, 19700173.
19. Cheon SM, Ha MS, Park MJ, Kim JW. Nonmotor symptoms of Parkinson's disease: prevalence and awareness of patients and families. Parkinsonism Relat Disord 2008, 14:286-290. 10.1016/j.parkreldis.2007.09.002, 18042421.
20. Wang G, Hong Z, Cheng Q, Xiao Q, Wang Y, Zhang J, et al. Validation of the Chinese Non-Motor Symptoms Scale for Parkinson's disease: Results from a Chinese pilot study. Clin Neurol Neurosurg 2009, 111:523-526. 10.1016/j.clineuro.2009.02.005, 19297081.
21. Chaudhuri KR, Rudzinska M, Kies B, et al. Effect of Rotigotine on Non-Motor Symptom in subjects with Idiopathic Parkinson's Disease. Neurology 2010, 74(suppl.2):A299.